<--- Back to Details
First PageDocument Content
Stroke / Hematology / Cardiac dysrhythmia / Dabigatran / Apixaban / Rivaroxaban / CHADS2 score / Atrial fibrillation / Warfarin / Chemistry / Organic chemistry / Anticoagulants
Date: 2014-10-01 22:38:52
Stroke
Hematology
Cardiac dysrhythmia
Dabigatran
Apixaban
Rivaroxaban
CHADS2 score
Atrial fibrillation
Warfarin
Chemistry
Organic chemistry
Anticoagulants

Microsoft Word - ~docx

Add to Reading List

Source URL: pbs.gov.au

Download Document from Source Website

File Size: 136,25 KB

Share Document on Facebook

Similar Documents

CHADS2 Score H E R M ELINDA G. A B C E DE, M D H S A S S ISTA NT C L I N I CAL PRO F ES S OR UCI D E PA RTM ENT O F N E UROLOGY

CHADS2 Score H E R M ELINDA G. A B C E DE, M D H S A S S ISTA NT C L I N I CAL PRO F ES S OR UCI D E PA RTM ENT O F N E UROLOGY

DocID: 1lgor - View Document

Supplementary Material to Beyer-Westendorf et al. “Effectiveness and  safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry” (Thromb Haemost 2015; 113.6)

Supplementary Material to Beyer-Westendorf et al. “Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry” (Thromb Haemost 2015; 113.6)

DocID: 1gsBz - View Document

DecemberAnti-Thrombotic Choices for Reducing Risk of Stroke in Atrial Fibrillation The “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Preve

DecemberAnti-Thrombotic Choices for Reducing Risk of Stroke in Atrial Fibrillation The “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Preve

DocID: 1gs4w - View Document

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Atrial Fibrillation

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Atrial Fibrillation

DocID: 18nC9 - View Document

PDF Document

DocID: 17hZU - View Document